Compare MKC & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKC | RDY |
|---|---|---|
| Founded | 1889 | 1984 |
| Country | United States | India |
| Employees | 14100 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.8B |
| IPO Year | N/A | 2001 |
| Metric | MKC | RDY |
|---|---|---|
| Price | $52.39 | $12.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $67.00 | $16.90 |
| AVG Volume (30 Days) | ★ 5.1M | 3.0M |
| Earning Date | 03-31-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.80% | 0.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.24 | $7.72 |
| Revenue Next Year | $3.71 | $3.50 |
| P/E Ratio | $23.90 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.82 | $12.19 |
| 52 Week High | $73.84 | $15.67 |
| Indicator | MKC | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 35.72 |
| Support Level | $45.45 | $12.19 |
| Resistance Level | $54.71 | $13.96 |
| Average True Range (ATR) | 1.60 | 0.38 |
| MACD | 0.07 | -0.23 |
| Stochastic Oscillator | 72.76 | 1.83 |
In its 135-plus-year history, McCormick has become the leading global manufacturer of spices, herbs, extracts, seasonings, and other flavorings. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula. This mix will be complemented by the pending addition of Unilever's food brands, primarily Knorr cooking aids and Hellmann's mayonnaise. After the deal close, the combined business is slated to generate 70% of sales from consumers and 30% from restaurants and other packaged food and beverage manufacturers. Around 40% of sales are slated to come from faster-growing emerging markets, with Europe (23%) and North America (36%) accounting for the remainder.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.